Introduction
Multiple myeloma often requires combination treatment and ongoing medical management. Sarclisa is a targeted monoclonal antibody used with other medicines in several treatment settings for adults with multiple myeloma.
Because Sarclisa is administered as an intravenous infusion and is used as part of combination therapy, treatment can involve significant medication-access considerations. For eligible patients, Prescription Hope may help navigate prescription assistance and treatment costs.
What Is The Sarclisa Patient Assistance Program?
Sadly, the cost of specialty medications and other brand-name medications continue to rise. Today, many Americans struggle to afford their prescriptions, with many avoiding filling their prescriptions due to the costs.
Pharmaceutical manufacturers understand that some of their products may be too expensive for the average American to pay. To help alleviate this issue, manufacturers often offer patient assistance programs.
These provide qualified patients with access to their needed brand-name medications at affordable rates.
However, many of these programs have a reputation for being difficult to apply for and include complex bureaucratic approval processes.
Thankfully, Prescription Hope offers a solution.
How Expert Advocates Help Make Medication More Affordable
Patient-Focused Medication Support
Prescription Hope offers Sarclisa medication support services by helping patients apply to the Sarclisa patient assistance program.
Our team of patient advocates completes forms, collects documents and signatures, connects with healthcare providers, and manages communication with the manufacturers. All so you don’t have to.
Ongoing Prescription Assistance
Prescription Hope’s multiple myeloma prescription assistance services don’t end after a qualified patient receives their initial shipment of medication. Our team continues to manage refill scheduling, document updates, issue resolution, yearly renewals, and more.
Sarclisa Price Comparison
vs
Estimated Retail Price*
30-Day Supply
Prescription Hope Price
Per Month, NO Matter The Retail Price
*Source: Drugs.com
Simplified Access to Specialty Therapies
While many programs provide limited assistance or help throughout the process, Prescription Hope offers all services for a simple and low service rate of $70.00 per month, per medication.
Plus, if we can’t help a patient save, then they pay nothing!
Sarclisa Patient Assistance Eligibility
Those looking for Sarclisa patient assistance should know the program’s specific eligibility criteria. However, all programs differ, so we recommend enrolling with Prescription Hope to learn more.
All programs maintain criteria that fall under several general categories:
Income: Even though every program uses income as a direct qualification, each program’s acceptable income range may differ.
Insurance: All programs use insurance as a standard. However, some programs require a qualified patient to have no insurance, while others allow some form of coverage.
Prescription: All programs require qualified patients to have a valid prescription for the medication covered by the program.
Residency: Qualified patients must be legal U.S. residents.
Simple Enrollment With Expert Support
Enrolling in the Sarclisa patient assistance program through Prescription Hope is a simple 6-step process:
- Submit Your Information: Filling out our online enrollment form only takes a few minutes.
- Speak with a Patient Advocate: After we receive your enrollment form, a patient advocate will contact you within 1-2 business days.
- Gather Required Documentation: Following a quick prequalification, our team collects all necessary documents.
- Coordinate with Your Healthcare Provider: We connect with your healthcare provider to gather needed signatures.
- Complete and Submit Your Application: Once everything is in order, our patient advocates submit your application packet and follow up with the manufacturer throughout the processing stage.
- Receive Your Medication: After approval, qualified patients can typically expect to receive their medication within 2 weeks. All medications ship directly from the manufacturer to the patient’s home or doctor’s office.
Prescription Hope is not a pharmacy or manufacturer and does not handle medication at any time.
Understanding Sarclisa
How Sarclisa Works
Sarclisa is a CD38-directed cytolytic antibody that binds to CD38, a protein expressed on multiple myeloma cells. This can directly induce tumor-cell death and activate immune mechanisms including antibody-dependent cellular cytotoxicity, antibody-dependent cellular phagocytosis, and complement-dependent cytotoxicity.
This medication also inhibits CD38 enzymatic activity and affects certain immune cells.
What Conditions Does Sarclisa Treat?
Sarclisa is approved in combination with other medicines for adults with multiple myeloma. With pomalidomide and dexamethasone, it is used for adults who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor.
With carfilzomib and dexamethasone, Sarclisa is used for adults with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy. With bortezomib, lenalidomide, and dexamethasone, it is used for adults with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant.
Benefits of Treatment
Sarclisa is used as part of combination therapy to target and eliminate multiple myeloma cells. Clinical studies found that adding this medication to certain combination regimens improved progression-free survival compared with the corresponding treatment regimens alone. Sarclisa is administered by intravenous infusion on a recurring schedule that varies according to the combination regimen.
Important Safety Information and Side Effects
Infusion-Related Reactions
Sarclisa can cause infusion-related reactions during or shortly after administration, including severe or life-threatening reactions. Premedication is required before infusion. Grade 4 infusion-related reactions or anaphylactic reactions require permanent discontinuation.
Infections
Sarclisa can cause serious, including fatal, infections. Patients should be monitored for infections and treated appropriately. Antimicrobial prophylaxis may be appropriate.
Neutropenia
This medication can also cause severe neutropenia and neutropenic infections. Blood counts should be monitored, and treatment interruptions or growth-factor support may be needed.
Second Primary Malignancies
An increased incidence of second primary malignancies has been observed in patients receiving Sarclisa-containing regimens. Patients should be monitored.
Laboratory-Test Interference
Sarclisa can interfere with blood compatibility testing, including indirect antiglobulin tests, antibody screening, and crossmatching. Blood type and screening should be performed before the first infusion, and blood-bank personnel should be informed that the patient is receiving Sarclisa.
Sarclisa can also interfere with serum protein electrophoresis and immunofixation tests used to assess M-protein and monitor multiple myeloma. This interference can affect interpretation of treatment-response testing.
Heart Failure
Heart failure has been reported with the combination of Sarclisa, carfilzomib, and dexamethasone. Patients receiving this combination should be monitored for cardiac complications.
Embryo-Fetal Toxicity
This medication may cause fetal harm. Human pregnancy data are insufficient, and IgG1 antibodies can cross the placenta. Females of reproductive potential should use effective contraception during treatment and for five months after the last dose. Pomalidomide- or lenalidomide-containing regimens have additional pregnancy-related restrictions.
Breastfeeding
There are no available data on isatuximab-irfc in human milk or its effects on a breastfed child. Women should not breastfeed during treatment with this medication.
Contraindication
Sarclisa is contraindicated in patients with severe hypersensitivity to isatuximab-irfc or any of its excipients.
Common Side Effects
Common adverse reactions vary according to the combination regimen. Reported reactions include upper respiratory tract infections, infusion-related reactions, pneumonia, diarrhea, fatigue, hypertension, shortness of breath, insomnia, bronchitis, cough, back pain, peripheral sensory neuropathy, musculoskeletal pain, cataract, constipation, peripheral edema, rash, and COVID-19.
Decreased blood-cell counts, including hemoglobin, neutrophils, lymphocytes, platelets, and leukocytes, are also common laboratory abnormalities.
Access to Multiple Medications
Patients who need specialty medication access often need assistance for multiple prescriptions.
Prescription Hope may be able to help. With a list of hundreds of accessible medications, we often help qualified patients access all of their brand-name medications.
And no matter how many medications, our service rate remains a simple and low $70.00 per month, per medication.
Why Choose Prescription Hope for Sarclisa Assistance?
Patient-Focused Medication Support
Prescription Hope doesn’t just provide Sarclisa assistance services. For 20 years, we have helped qualified patients access their brand-name medications across the nation.
Simplified Access to Specialty Therapies
We offer a simple way to save. Our team manages the application process from start to finish, handling form completion, document and signature gathering, communication with healthcare providers and manufacturers, and more.
Ongoing Prescription Assistance
Once a patient qualifies and receives their medication, our team continues to handle the administrative tasks associated with patient assistance programs. We continue to coordinate with the manufacturer, handle refill scheduling, take care of document updates, resolve unforeseen issues, manage yearly renewals, and more.
If you need access to Sarclisa patient assistance and ongoing medication support services, then be sure to enroll with Prescription Hope today.